Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

With healthcare costs dominating the conversation in recent years, the topic of employer-covered healthcare is a key issue.

Novo Nordisk secured Pharmashell access for up to five peptide programs, targeting long-acting injectable profiles and offering Nanexa >$1.33B total consideration plus low single-digit royalties.

Jun Gong, MD, associate professor of medicine and medical director of colorectal cancer at Cedars-Sinai, spoke with ...

FDA cleared belzutifan 120 mg plus lenvatinib 20 mg daily for advanced RCC with a clear cell component after prior PD-1/PD-L1 inhibitor exposure. LITESPARK-011 randomized 747 patients to ...

InnoCare Pharma and Eli Lilly ink a multibillion-dollar research collaboration, FDA approves Lilly's once-weekly insulin ...

Yale University and a seasoned life science entrepreneur with over 17 years of experience building, investing in, and scaling biotechnology startups. He founded the company in 2018, originally spun ...

A key factor of this is the growing acceptance of RWD in trial design. The agency hopes that by allowing RWD collected by qualified research institutions, drug developers will not only be able to move ...

Drug-delivery failures — not flawed science — are the hidden driver of late-stage trial failures. The long, complex process that it takes to successfully bring a drug to market is one of the biggest ...

FDA authorization is underpinned by four global Phase III QWINT studies showing non-inferior A1C lowering versus glargine ...

The agreement provides up to $100 million upfront/near-term and up to ~$3.25 billion in milestones, plus single-digit tiered royalties, reflecting high optionality typical of early discovery ...

EVERSANA's Jen Norton talks about how AI is reshaping market access strategy, a new analysis from MIT and Harvard Business ...